SEC Comment Letter 0000000000-23-009073 to PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC.
Date: Aug. 18, 2023 · CIK: 0001625101 · Accession: 0000000000-23-009073
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273944
Letter
United States securities and exchange commission logo August 18, 2023 Kevin Danahy Chief Executive Officer Pulse Biosciences, Inc. 3957 Point Eden Way Hayward, California 94545 Re:Pulse Biosciences, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273944 Dear Kevin Danahy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at 202-551-4511 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Adam Finerman
Show Raw Text
United States securities and exchange commission logo
August 18, 2023
Kevin Danahy
Chief Executive Officer
Pulse Biosciences, Inc.
3957 Point Eden Way
Hayward, California 94545
Re:Pulse Biosciences, Inc.
Registration Statement on Form S-3
Filed August 11, 2023
File No. 333-273944
Dear Kevin Danahy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Ansart at 202-551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Adam Finerman